Mizuho Lowers Teva Pharmaceutical Industries Ltd (TEVA) Price Target to $25.00

Mizuho Lowers Teva Pharmaceutical Industries Ltd (TEVA) Price Target to $25.00

A number of other equities research analysts have also recently weighed in on TEVA. Bank of America Corp upgraded shares of Teva Pharmaceutical Industries from a neutral rating to a buy rating in a research report on Tuesday, January 31st. Barclays PLC dropped their price target on shares of Teva Pharmaceutical Industries from $46.00 to $38.00 and set an equal weight rating for the company in a research report on Tuesday, January 31st. Deutsche Bank AG reiterated a buy rating and set a $48.00 price target on shares of Teva Pharmaceutical Industries in a research report on Tuesday, January 31st. Oppenheimer Holdings Inc. reiterated an outperform rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, February 1st. Finally, Maxim Group set a $41.00 price target on shares of Teva Pharmaceutical Industries and gave the company a hold rating in a research report on Wednesday, February 1st. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of Buy and an average target price of $43.91.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) had its price target cut by Mizuho from $29.00 to $25.00 in a research note published on Thursday. They currently have an underperform rating on the stock.

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at 27.82 on Thursday. Teva Pharmaceutical Industries has a 52-week low of $27.76 and a 52-week high of $56.44. The firm has a 50-day moving average of $30.85 and a 200 day moving average of $33.96. The stock has a market capitalization of $28.27 billion, a PE ratio of 356.67 and a beta of 0.58.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Thursday, May 11th. The company reported $1.06 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.06. Teva Pharmaceutical Industries had a net margin of 1.50% and a return on equity of 17.46%. The business had revenue of $5.63 billion during the quarter, compared to analysts’ expectations of $5.69 billion. During the same period last year, the business earned $1.20 earnings per share. The business’s revenue for the quarter was up 17.0% on a year-over-year basis. Equities research analysts forecast that Teva Pharmaceutical Industries will post $4.78 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 22nd. Shareholders of record on Monday, June 5th will be issued a dividend of $0.34 per share. The ex-dividend date is Thursday, June 1st. This represents a $1.36 dividend on an annualized basis and a yield of 4.89%. Teva Pharmaceutical Industries’s payout ratio is currently 1,657.38%.

A number of hedge funds have recently added to or reduced their stakes in TEVA. Cribstone Capital Management LLC boosted its stake in Teva Pharmaceutical Industries by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock worth $101,000 after buying an additional 100 shares during the last quarter. Bronfman E.L. Rothschild L.P. boosted its stake in Teva Pharmaceutical Industries by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after buying an additional 261 shares during the last quarter. FNY Managed Accounts LLC bought a new stake in Teva Pharmaceutical Industries during the first quarter worth $123,000. Sterling Investment Advisors Ltd. boosted its stake in Teva Pharmaceutical Industries by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after buying an additional 100 shares during the last quarter. Finally, Financial Architects Inc boosted its stake in Teva Pharmaceutical Industries by 2.3% in the first quarter. Financial Architects Inc now owns 4,443 shares of the company’s stock worth $143,000 after buying an additional 100 shares during the last quarter. 55.03% of the stock is currently owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “TEVA”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment